Allovir Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
2024-10-29

* Allovir Inc is expected to show no change in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024

*

* ​LSEG's mean analyst estimate for Allovir Inc is for a loss of 9 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 1.6% in the last three months. ​

* Wall Street's median 12-month price target for Allovir Inc is $0.95​, above​ its last closing price of $0.85. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.07 -0.10 -0.05 Beat 52.4

Mar. 31 2024 -0.17 -0.16 -0.26 Missed -66

Dec. 31 2023 -0.46 -0.43 -0.36 Beat 15.9​

Sep. 30 2023 -0.41 -0.42 -0.39 Beat 6.3

​​Jun. -0.43 -0.45 -0.48 Missed -6.7

30 2023

Mar. 31 2023 -0.46 -0.46 -0.44 Beat 5.4​

Dec. 31 2022 -0.56 -0.54 -0.37 Beat 31.9

Sep. 30 2022 -0.52 -0.53 -0.50 Beat 5.1

This summary was machine generated October 29 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10